MedTrace Logo

Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

NCT04803240 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2021-03-17

No results posted yet for this study

Summary

Multi-centre, international, non-interventional, prospective survey

Conditions

  • Dry Eye

Interventions

DEVICE

Thealoz Duo

Non applicable

Sponsors & Collaborators

  • Iris Pharma

    collaborator INDUSTRY

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

  • Antonio MATEO, Dr. · Hospital Miguel Servet

  • Philip BUCKHURST, Dr. · University of Plymouth

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-12-30
Completion
2020-03-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803240 on ClinicalTrials.gov